X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (15) 15
oncology (13) 13
humans (11) 11
nivolumab (9) 9
immunotherapy (7) 7
docetaxel (6) 6
immunology (6) 6
pd-1 blockade (6) 6
abstracts (5) 5
adult (5) 5
animals (5) 5
b. poster abstracts (5) 5
cancer (5) 5
female (5) 5
ipilimumab (5) 5
melanoma (5) 5
middle aged (5) 5
pembrolizumab (5) 5
therapy (5) 5
tumors (5) 5
analysis (4) 4
article (4) 4
care and treatment (4) 4
health aspects (4) 4
infections (4) 4
male (4) 4
mice (4) 4
open-label (4) 4
resistance (4) 4
advanced melanoma (3) 3
aggressive fibromatosis (3) 3
b7-h1 antigen - antagonists & inhibitors (3) 3
ctla-4 blockade (3) 3
disease models, animal (3) 3
management (3) 3
mutation (3) 3
pd-1 (3) 3
programmed cell death 1 receptor - antagonists & inhibitors (3) 3
research (3) 3
[ sdv.can ] life sciences [q-bio]/cancer (2) 2
aged (2) 2
aged, 80 and over (2) 2
anti-pd-1 (2) 2
antibodies, monoclonal - therapeutic use (2) 2
apoptosis (2) 2
beta catenin - metabolism (2) 2
beta-catenin (2) 2
cancer-immunotherapy (2) 2
cell lung-cancer (2) 2
cell transformation, neoplastic (2) 2
dermatitis (2) 2
desmoid tumor (2) 2
dna repair - genetics (2) 2
emergency granulopoiesis (2) 2
expression (2) 2
familial adenomatous polyposis (2) 2
fanconi dna repair pathway (2) 2
fibromatosis, aggressive - pathology (2) 2
genes (2) 2
genetic aspects (2) 2
hematopoiesis - genetics (2) 2
hepatitis (2) 2
hepatitis b (2) 2
hiv (2) 2
immunohistochemistry (2) 2
immunotherapy - adverse effects (2) 2
immunotherapy - methods (2) 2
infection - complications (2) 2
infection - genetics (2) 2
irae (2) 2
landscape (2) 2
leukemia (2) 2
leukemia - complications (2) 2
leukemia - genetics (2) 2
life sciences (2) 2
medical colleges (2) 2
methods (2) 2
neoplasms - drug therapy (2) 2
neutropenia (2) 2
neutropenia - complications (2) 2
neutropenia - genetics (2) 2
neutrophils (2) 2
neutrophils - physiology (2) 2
original reports (2) 2
paclitaxel (2) 2
pathology (2) 2
patients (2) 2
pd-1 protein (2) 2
pd-l1 protein (2) 2
physiological aspects (2) 2
proteins (2) 2
stem-cells (2) 2
surgery (2) 2
toxicity (2) 2
transcription factors - genetics (2) 2
transcription factors - metabolism (2) 2
transcriptional activation (2) 2
tumor mutational burden (2) 2
wound healing (2) 2
β-catenin (2) 2
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Science, ISSN 0036-8075, 01/2018, Volume 359, Issue 6371, pp. 91 - 97
Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis induce sustained clinical responses in a sizable minority of cancer patients. We found that... 
CELL LUNG-CANCER | MELANOMA | MICROENVIRONMENT | INTESTINAL MICROBIOTA | CYCLOPHOSPHAMIDE | PD-1 BLOCKADE | MULTIDISCIPLINARY SCIENCES | GENES | RESISTANCE | ANTITUMOR IMMUNITY | NIVOLUMAB | CD4 Antigens - immunology | Immunotherapy - methods | Humans | Antibodies, Monoclonal - therapeutic use | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Gastrointestinal Microbiome - genetics | Fecal Microbiota Transplantation | Anti-Bacterial Agents - therapeutic use | Feces - microbiology | Metagenome - genetics | Neoplasms - therapy | Animals | Receptors, CCR - immunology | Interleukin-12 - immunology | Receptors, CXCR3 - immunology | T-Lymphocytes - immunology | Mice | Gastrointestinal Microbiome - immunology | Verrucomicrobia - genetics | Verrucomicrobia - immunology | Care and treatment | Cell receptors | Microbiota (Symbiotic organisms) | Immunotherapy | Epithelial tumors | Physiological aspects | Health aspects | Methods | Apoptosis | PD-1 protein | Interleukin | Microbiomes | Transplantation | Lymphocytes T | Anticancer properties | Microbiota | Lymphocytes | Bacteria | Feces | Supplementation | Gnotobiotics | Kidneys | Melanoma | Dietary supplements | Interleukin 12 | Abundance | CXCR3 protein | Patients | CD4 antigen | Immune checkpoint | Antibiotics | Lungs | Flora | PD-L1 protein | Relative abundance | Antitumor activity | CCR9 protein | Tumors | Kidney transplantation | Cancer | Life Sciences
Journal Article
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2017, Volume 35, Issue 7, pp. 709 - 717
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 07/2018, Volume 36, Issue 19, pp. 1905 - 1912
PurposeAlthough programmed death (PD)-1 pathway inhibitors are now used in nearly all patients with advanced non-small-cell lung cancer (NSCLC), the large... 
PEMBROLIZUMAB | THERAPY | ONCOLOGY | ADVANCED MELANOMA | DISEASE | OPEN-LABEL | NIVOLUMAB | DOCETAXEL | IPILIMUMAB | RAPID COMMUNICATION
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 10/2018, Volume 36, Issue 28, pp. 2872 - 2878
PurposeTreatment with programmed cell death-1 or programmed death ligand 1 (PD-(L)1) inhibitors is now standard therapy for patients with lung cancer. The... 
DEXAMETHASONE | PEMBROLIZUMAB | ONCOLOGY | DYSPNEA | FATIGUE | DOUBLE-BLIND | OPEN-LABEL | DOCETAXEL | ADVERSE EVENTS | T-CELLS
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2017, Volume 35, Issue 15_suppl, pp. 9081 - 9081
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 02/2019, Volume 25, Issue 3, pp. 1063 - 1069
Purpose: Tumor mutation burden (TMB) is a biomarker of response to immune checkpoint blockade (ICB). The impact of TMB on outcomes with targeted therapies has... 
CTLA-4 BLOCKADE | FACTOR-RECEPTOR GENE | GEFITINIB | CARBOPLATIN | OSIMERTINIB | ONCOLOGY | LANDSCAPE | ADENOCARCINOMA | SENSITIVITY | NEOANTIGENS | PACLITAXEL
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2018, Volume 36, Issue 15_suppl, pp. 9042 - 9042
Journal Article
Cancer Discovery, ISSN 2159-8274, 07/2018, Volume 8, Issue 7, pp. 822 - 835
KRAS is the most common oncogenic driver in lung adenocarcinoma (LUAC). We previously reported that STK11/LKB1 (KL) or TP53 (KP) comutations define distinct... 
CTLA-4 BLOCKADE | CANCER-PATIENTS | MELANOMA | ONCOLOGY | COOCCURRING GENOMIC ALTERATIONS | OPEN-LABEL | RANDOMIZED CONTROLLED-TRIAL | NIVOLUMAB | LKB1 LOSS | DOCETAXEL | TUMOR MICROENVIRONMENT | non-small cell lung cancer | PD-1 blockade | STK11 | KRAS | LKB1 | lung adenocarcinoma
Journal Article
Gynecologic Oncology Reports, ISSN 2352-5789, 05/2018, Volume 24, pp. 94 - 98
Multiple primary tumors (MPTs) are defined as two or more separate synchronous or metachronous neoplasms occurring in different sites in the same individual.... 
Tumor mutational burden | Next-generation sequencing | Immunotherapy | Multiple primary tumors
Journal Article
Cancer Research, ISSN 0008-5472, 04/2011, Volume 71, Issue 8 Supplement, pp. 2292 - 2292
Journal Article